Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVONIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVONIX's regulatory disclosures and financial reporting.
Novonix Limited is reporting the issue and ASX quotation of additional ordinary fully paid shares resulting from the conversion of performance rights under an employee incentive scheme. The new shares are in an existing quoted class and will rank equally with other ordinary shares from their issue date.
No cash is being paid for these shares, with the consideration valued at approximately AUD 0.265 per share. Following this quotation, Novonix states that its quoted ordinary share capital on ASX will comprise 861,442,940 ordinary fully paid shares, alongside several unquoted classes including performance rights, options and convertible notes.
NOVONIX Limited filed an amended Form 6-K to correct formatting in its previously furnished AGM presentation, confirming no substantive changes to the underlying content. The filing also provides the Chairman’s address, updated strategy, and detailed voting results from the April 15, 2026 Annual General Meeting.
The Chairman highlights 2025 as a key year, including delivery of the first mass-production, commercial-grade synthetic graphite sample and installation of four graphitization furnaces at the Riverside facility in Chattanooga to support Panasonic Energy qualification. NOVONIX expects mass production of industrial-grade synthetic graphite to begin in 2026 and now anticipates mass production of battery-grade anode material for Panasonic Energy in the second half of 2027.
The company executed a funding agreement with Yorkville Advisors for access to US$100 million in convertible debentures, sold its Mt Dromedary natural graphite project, and agreed a binding term sheet to divest its Battery Technology Solutions division while retaining 15% ownership. NOVONIX reports contracted offtakes including a four‑year, 10,000‑tonne commitment and a five‑year, minimum 32,000‑tonne commitment, both subject to successful qualification. All AGM resolutions, including director re‑elections, performance rights, share rights, and additional 10% placement capacity, were carried by strong majorities.
NOVONIX Limited has reported the issue of new shares on the ASX following the conversion of performance rights under an employee incentive scheme. The company will have 861,410,374 ordinary fully paid shares quoted on ASX after the quotation of 13,442 additional shares issued on April 17, 2026.
The new shares are issued for non-cash consideration linked to performance rights valued at approximately AUD 0.295 per share. NOVONIX also has unquoted performance rights, options with various expiries and prices, and convertible notes on issue in addition to its quoted share capital.
NOVONIX Limited provides an update from its Annual General Meeting, outlining progress toward large-scale U.S. synthetic graphite production and confirming all AGM resolutions passed by poll. The company has installed four graphitization furnaces at its Chattanooga Riverside facility and delivered its first mass production, commercial-grade synthetic graphite sample for industrial uses in 2025. NOVONIX expects mass production of industrial-grade synthetic graphite to start in 2026 and now anticipates mass production of battery-grade anode material for Panasonic Energy in the second half of 2027, following rigorous qualification processes. It has invested about $200 million in Chattanooga operations and is planning expansion to 50,000 tonnes per annum, with potential capital savings of more than $200 million if capacity is consolidated on one site. Funding support includes a $100 million convertible debenture facility with Yorkville Advisors, a $100 million CMEI grant for Riverside, and a $754 million conditionally committed DOE loan to support future capacity. NOVONIX holds binding offtake commitments totaling 10,000 tonnes over four years and at least 32,000 tonnes over five years, subject to product qualification, and continues discussions with additional customers while also divesting non-core assets to focus on U.S. synthetic graphite.
NOVONIX Limited reports that the U.S. Government has certified its Riverside synthetic graphite project for US$103 million in Section 48C Advanced Energy Project tax credits. NOVONIX will receive these credits once its first 11,000 tpa of production is placed in service before 7 April 2028. The credits are transferable and can be sold to a third party, supporting the company’s plan to build a domestic synthetic graphite supply chain from its Chattanooga, Tennessee operations.
NOVONIX Limited filed a Form 6-K detailing the issue of additional ordinary shares on the ASX following the conversion of performance rights. The company is applying for quotation of 31,777 NVX ordinary fully paid shares, issued on 26 March 2026 as new securities in an existing quoted class.
The shares were issued for non-cash consideration linked to the performance rights, with an estimated value of AUD 0.29 per share. After this issuance, the total number of NVX ordinary fully paid shares quoted on ASX is 861,396,932. The company also discloses unquoted securities, including performance rights, options, and convertible notes that remain on issue.
Novonix Limited has filed a Form 6-K as a foreign private issuer for March 2026. The filing primarily furnishes an ASX announcement titled “Nasdaq Notice of Minimum Bid Price Deficiency” dated March 18, 2026, indicating the company is addressing a Nasdaq minimum bid price compliance matter.
Novonix Limited has called its 2026 Annual General Meeting for 15 April 2026 as a hybrid event in Brisbane and online, where shareholders can watch, ask questions and vote virtually or in person.
Key items include receiving the FY25 financial and remuneration reports, advisory approval of the 2025 Remuneration Report, and re-election of directors Admiral Robert Natter and Ronald Edmonds. Shareholders are asked to re-approve the Performance Rights Plan for up to 35,000,000 Performance Rights and to grant CEO Michael O’Kronley 5,862,567 FY26 Performance Rights tied to three-year relative TSR and a 2028 revenue modifier. Resolutions also seek approval for 1,371,566 FY26 Share Rights across Phillips 66 Company and six non-executive directors, and an additional 10% share placement capacity under ASX Listing Rule 7.1A, taking potential placement headroom to 25% if approved.
NOVONIX Ltd’s Chief Financial Officer Robert Buell Long filed an initial ownership report showing his equity-based incentives. The Form 3 lists performance rights that can convert into 1,363,398 ordinary shares expiring in 2028, 2,069,142 shares expiring in 2029, and 1,144,130 shares expiring in 2027, all with a conversion price of $0.0000.
NOVONIX Ltd reported the initial equity holdings of Chief Legal and Risk Officer Kimberly J. Heimert. The filing lists two blocks of performance rights that can convert to ordinary shares at an exercise price of $0.0000 per share.
One block relates to 489,818 underlying ordinary shares with an exercise date on December 31, 2027 and expiration on December 31, 2028. The second block relates to 1,724,285 underlying ordinary shares with an exercise date on December 31, 2028 and expiration on December 31, 2029. The filing does not show any buy or sell transactions, only these derivative holdings.